Financial - Capital Markets
Build Your Comparison
Side-by-side financial analysisStock Comparison
NAKA vs WELL vs VTR vs OPRX vs OHI vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
REIT - Healthcare Facilities
REIT - Healthcare Facilities
Medical - Healthcare Information Services
REIT - Healthcare Facilities
Beverages - Non-Alcoholic
NAKA vs WELL vs VTR vs OPRX vs OHI vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||||
|---|---|---|---|---|---|---|
| Industry | Financial - Capital Markets | REIT - Healthcare Facilities | REIT - Healthcare Facilities | Medical - Healthcare Information Services | REIT - Healthcare Facilities | Beverages - Non-Alcoholic |
| Market Cap | $79M | $149.11B | $39.68B | $100M | $13.46B | $348.25B |
| Revenue (TTM) | $4M | $11.63B | $6.13B | $107M | $1.24B | $49.28B |
| Net Income (TTM) | $-290M | $1.43B | $260M | $7M | $632M | $13.70B |
| Gross Margin | -376.0% | 39.1% | -4.3% | 69.0% | 85.5% | 61.7% |
| Operating Margin | -82.2% | 4.4% | 13.4% | 13.6% | 64.3% | 29.3% |
| Forward P/E | — | 73.5x | 133.8x | 5.6x | 22.7x | 24.7x |
| Total Debt | $210M | $21.38B | $13.22B | $26M | $4.26B | $45.49B |
| Cash & Equiv. | $23M | $5.03B | $741M | $23M | $27M | $10.27B |
NAKA vs WELL vs VTR vs OPRX vs OHI vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 24 | Jun 26 | Return |
|---|---|---|---|
| Nakamoto Inc. (NAKA) | 100 | 3.7 | -96.3% |
| Welltower Inc. (WELL) | 100 | 205.3 | +105.3% |
| Ventas, Inc. (VTR) | 100 | 166.1 | +66.1% |
| OptimizeRx Corporat… (OPRX) | 100 | 44.1 | -55.9% |
| Omega Healthcare In… (OHI) | 100 | 139.8 | +39.8% |
| The Coca-Cola Compa… (KO) | 100 | 128.6 | +28.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NAKA vs WELL vs VTR vs OPRX vs OHI vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 6 stocks, NAKA doesn't own a clear edge in any measured category.
WELL carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 2 yrs, beta 0.04, yield 1.3%
- 229.1% 10Y total return vs KO's 118.2%
- Lower volatility, beta 0.04, Low D/E 49.5%, current ratio 5.34x
- Beta 0.04, yield 1.3%, current ratio 5.34x
VTR doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.
OPRX ranks third and is worth considering specifically for growth exposure.
- Rev growth 18.8%, EPS growth 124.5%, 3Y rev CAGR 20.6%
- Lower P/E (5.6x vs 24.7x)
OHI is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.97 vs KO's 2.21
- 51.0% margin vs NAKA's -74.0%
- 5.6% yield, vs KO's 2.5%, (2 stocks pay no dividend)
KO is the clearest fit if your priority is efficiency.
- 13.1% ROA vs NAKA's -56.5%, ROIC 15.8% vs -42.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 35.8% FFO/revenue growth vs NAKA's -33.0% | |
| Value | Lower P/E (5.6x vs 24.7x) | |
| Quality / Margins | 51.0% margin vs NAKA's -74.0% | |
| Stability / Safety | Beta 0.04 vs NAKA's 2.88 | |
| Dividends | 5.6% yield, vs KO's 2.5%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +43.3% vs NAKA's -99.3% | |
| Efficiency (ROA) | 13.1% ROA vs NAKA's -56.5%, ROIC 15.8% vs -42.1% |
NAKA vs WELL vs VTR vs OPRX vs OHI vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NAKA vs WELL vs VTR vs OPRX vs OHI vs KO — Financial Metrics
Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
OHI leads in 1 of 6 categories
OPRX leads 1 • KO leads 1 • WELL leads 1 • NAKA leads 0 • VTR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
OHI leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 12573.5x NAKA's $4M. OHI is the more profitable business, keeping 51.0% of every revenue dollar as net income compared to NAKA's -74.0%. On growth, NAKA holds the edge at +3.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4M | $11.6B | $6.1B | $107M | $1.2B | $49.3B |
| EBITDAEarnings before interest/tax | -$320M | $2.8B | $2.3B | $19M | $1.1B | $15.5B |
| Net IncomeAfter-tax profit | -$290M | $1.4B | $260M | $7M | $632M | $13.7B |
| Free Cash FlowCash after capex | -$46M | $2.5B | $1.4B | $14M | $912M | $12.6B |
| Gross MarginGross profit ÷ Revenue | -3.8% | +39.1% | -4.3% | +69.0% | +85.5% | +61.7% |
| Operating MarginEBIT ÷ Revenue | -82.2% | +4.4% | +13.4% | +13.6% | +64.3% | +29.3% |
| Net MarginNet income ÷ Revenue | -74.0% | +12.3% | +4.2% | +6.4% | +51.0% | +27.8% |
| FCF MarginFCF ÷ Revenue | -11.7% | +21.9% | +22.4% | +13.4% | +73.6% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.6% | +40.3% | +22.0% | -9.5% | +16.7% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -88.4% | +22.5% | 0.0% | +78.0% | +42.4% | +18.2% |
Valuation Metrics
OPRX leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 19.7x trailing earnings, OPRX trades at a 87% valuation discount to VTR's 154.6x P/E. Adjusting for growth (PEG ratio), OHI offers better value at 1.00x vs KO's 2.38x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Market CapShares × price | $79M | $149.1B | $39.7B | $100M | $13.5B | $348.2B |
| Enterprise ValueMkt cap + debt − cash | $266M | $165.5B | $52.2B | $103M | $17.7B | $383.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.43x | 153.11x | 154.56x | 19.70x | 23.30x | 26.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 73.47x | 133.75x | 5.65x | 22.70x | 24.75x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 1.00x | 2.38x |
| EV / EBITDAEnterprise value multiple | — | 66.35x | 23.65x | 6.26x | 16.46x | 25.89x |
| Price / SalesMarket cap ÷ Revenue | 43.19x | 13.98x | 6.80x | 0.91x | 11.24x | 7.26x |
| Price / BookPrice ÷ Book value/share | 0.10x | 3.35x | 3.07x | 0.79x | 2.58x | 10.18x |
| Price / FCFMarket cap ÷ FCF | — | 52.36x | 30.14x | 5.35x | 15.32x | 65.76x |
Profitability & Efficiency
KO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-85 for NAKA. OPRX carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), WELL scores 7/9 vs NAKA's 2/9, reflecting strong financial health.
| Metric | ||||||
|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -84.8% | +3.5% | +2.1% | +5.5% | +11.9% | +41.1% |
| ROA (TTM)Return on assets | -56.5% | +2.3% | +1.0% | +4.0% | +6.1% | +13.1% |
| ROICReturn on invested capital | -42.1% | +0.5% | +2.5% | +6.8% | +6.0% | +15.8% |
| ROCEReturn on capital employed | -76.2% | +0.6% | +3.2% | +7.8% | +7.9% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 6 | 7 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.41x | 0.49x | 1.05x | 0.20x | 0.78x | 1.33x |
| Net DebtTotal debt minus cash | $187M | $16.3B | $12.5B | $3M | $4.2B | $35.2B |
| Cash & Equiv.Liquid assets | $23M | $5.0B | $741M | $23M | $27M | $10.3B |
| Total DebtShort + long-term debt | $210M | $21.4B | $13.2B | $26M | $4.3B | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | -24.72x | 0.26x | 1.40x | 2.84x | 3.83x | 10.70x |
Total Returns (Dividends Reinvested)
WELL leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WELL five years ago would be worth $27,819 today (with dividends reinvested), compared to $374 for NAKA. Over the past 12 months, WELL leads with a +43.3% total return vs NAKA's -99.3%. The 3-year compound annual growth rate (CAGR) favors WELL at 40.2% vs NAKA's -66.6% — a key indicator of consistent wealth creation.
| Metric | ||||||
|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -72.3% | +14.6% | +8.6% | -57.2% | +4.5% | +18.6% |
| 1-Year ReturnPast 12 months | -99.3% | +43.3% | +36.0% | -61.4% | +32.8% | +17.7% |
| 3-Year ReturnCumulative with dividends | -96.3% | +175.6% | +93.0% | -64.6% | +70.7% | +42.6% |
| 5-Year ReturnCumulative with dividends | -96.3% | +178.2% | +58.5% | -89.8% | +58.1% | +63.1% |
| 10-Year ReturnCumulative with dividends | -96.3% | +229.1% | +53.2% | +56.9% | +117.7% | +118.2% |
| CAGR (3Y)Annualised 3-year return | -66.6% | +40.2% | +24.5% | -29.2% | +19.5% | +12.6% |
Risk & Volatility
Evenly matched — OHI and KO each lead in 1 of 2 comparable metrics.
Risk & Volatility
OHI is the less volatile stock with a -0.21 beta — it tends to amplify market swings less than NAKA's 2.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 96.3% from its 52-week high vs NAKA's 0.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.88x | 0.04x | -0.11x | 2.18x | -0.21x | -0.20x |
| 52-Week HighHighest price in past year | $679.20 | $221.68 | $91.06 | $22.25 | $49.33 | $84.04 |
| 52-Week LowLowest price in past year | $0.38 | $148.97 | $61.76 | $4.57 | $35.70 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +0.7% | +96.0% | +91.7% | +23.9% | +91.7% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 35.4 | 55.6 | 50.7 | 46.1 | 48.1 | 60.8 |
| Avg Volume (50D)Average daily shares traded | 274K | 2.6M | 3.6M | 442K | 2.1M | 12.7M |
Analyst Outlook
Evenly matched — OHI and KO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NAKA as "Buy", WELL as "Buy", VTR as "Buy", OPRX as "Buy", OHI as "Hold", KO as "Buy". Consensus price targets imply 219.5% upside for OPRX (target: $17) vs 6.5% for KO (target: $86). For income investors, OHI offers the higher dividend yield at 5.56% vs WELL's 1.30%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $8.00 | $239.11 | $96.25 | $17.00 | $50.71 | $86.13 |
| # AnalystsCovering analysts | 2 | 34 | 32 | 15 | 28 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +1.3% | +2.2% | — | +5.6% | +2.5% |
| Dividend StreakConsecutive years of raises | 0 | 2 | 1 | 1 | 0 | 56 |
| Dividend / ShareAnnual DPS | — | $2.76 | $1.86 | — | $2.51 | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.4% | 0.0% | 0.0% | 0.0% | 0.0% | +0.2% |
OHI leads in 1 of 6 categories (Income & Cash Flow). OPRX leads in 1 (Valuation Metrics). 2 tied.
NAKA vs WELL vs VTR vs OPRX vs OHI vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NAKA or WELL or VTR or OPRX or OHI or KO a better buy right now?
For growth investors, Welltower Inc.
(WELL) is the stronger pick with 35. 8% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). OptimizeRx Corporation (OPRX) offers the better valuation at 19. 7x trailing P/E (5. 6x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NAKA or WELL or VTR or OPRX or OHI or KO?
On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 19.
7x versus Ventas, Inc. at 154. 6x. On forward P/E, OptimizeRx Corporation is actually cheaper at 5. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Omega Healthcare Investors, Inc. wins at 0. 97x versus The Coca-Cola Company's 2. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NAKA or WELL or VTR or OPRX or OHI or KO?
Over the past 5 years, Welltower Inc.
(WELL) delivered a total return of +178. 2%, compared to -96. 3% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: WELL returned +229. 1% versus NAKA's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NAKA or WELL or VTR or OPRX or OHI or KO?
By beta (market sensitivity over 5 years), Omega Healthcare Investors, Inc.
(OHI) is the lower-risk stock at -0. 21β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately -1476% more volatile than OHI relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 20% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
05Which is growing faster — NAKA or WELL or VTR or OPRX or OHI or KO?
By revenue growth (latest reported year), Welltower Inc.
(WELL) is pulling ahead at 35. 8% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: Ventas, Inc. grew EPS 184. 2% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, WELL leads at 22. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NAKA or WELL or VTR or OPRX or OHI or KO?
Omega Healthcare Investors, Inc.
(OHI) is the more profitable company, earning 49. 3% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 49. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OHI leads at 62. 6% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — OPRX leads at 63. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NAKA or WELL or VTR or OPRX or OHI or KO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Omega Healthcare Investors, Inc. (OHI) is the more undervalued stock at a PEG of 0. 97x versus The Coca-Cola Company's 2. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 5. 6x forward P/E versus 133. 8x for Ventas, Inc. — 128. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 219. 5% to $17. 00.
08Which pays a better dividend — NAKA or WELL or VTR or OPRX or OHI or KO?
In this comparison, OHI (5.
6% yield), KO (2. 5% yield), VTR (2. 2% yield), WELL (1. 3% yield) pay a dividend. NAKA, OPRX do not pay a meaningful dividend and should not be held primarily for income.
09Is NAKA or WELL or VTR or OPRX or OHI or KO better for a retirement portfolio?
For long-horizon retirement investors, Omega Healthcare Investors, Inc.
(OHI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 21), 5. 6% yield, +117. 7% 10Y return). Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OHI: +117. 7%, NAKA: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NAKA and WELL and VTR and OPRX and OHI and KO?
These companies operate in different sectors (NAKA (Financial Services) and WELL (Real Estate) and VTR (Real Estate) and OPRX (Healthcare) and OHI (Real Estate) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NAKA is a small-cap quality compounder stock; WELL is a mid-cap high-growth stock; VTR is a mid-cap high-growth stock; OPRX is a small-cap high-growth stock; OHI is a mid-cap income-oriented stock; KO is a large-cap quality compounder stock. WELL, VTR, OHI, KO pay a dividend while NAKA, OPRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.